Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary ...

“We’ve seen incredible momentum over the past year,” said Feross Aboukhadijeh, founder and CEO of Socket. “Our technology has ...

Editas Medicines has signed a $238 million biobucks pact to combine Genevant Science’s lipid nanoparticle (LNP) tech with the ...

This election season, our editorial board invited candidates in 39 state and local races to interview with us. We sat down ...